- Home
- » Tags
- » Acalabrutinib
Top View
- Non-Hodgkin Lymphoma Therapy Landscape
- Bladder Cancer
- Comparison of Acalabrutinib, a Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells
- 5-New and Emerging Drugs Tandem 2018 Agandhi FINAL 1.4.2018
- Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies Karl R
- 2017 Notches up Some Landmark Approvals David M Mintzer, MD
- Challenges with Approved Targeted Therapies Against Recurrent Mutations in CLL: a Place for New Actionable Targets
- Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance
- Cardiotoxicity of Novel Targeted Hematological Therapies
- Cutaneous Toxicities of New Targeted Cancer Therapies: Must Know for Diagnosis, Management, and Patient-Proxy Empowerment
- Cardiotoxicities of Tyrosine Kinase Inhibitors to Treat CML and CLL: Heart Attacks, Strokes, and Atrial Fibrillation Oh My!
- Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma: Review of Current Evidence and Future Directions
- Therapeutic Advances in Oncology
- Calquence, INN-Acalabrutinib
- Oncology Agents Policy #: Rx.01.67
- ACP-196 (Acalabrutinib) Date: 13 January 2016 Protocol: ACE-MY-001
- Combined Treatment with Acalabrutinib and Rapamycin Inhibits Glioma Stem Cells and Promotes Vascular Normalization by Downregulating BTK/Mtor/VEGF Signaling
- (Cll): What Are My Treatment Options?
- Acalabrutinib (ACP-196): a Selective Second-Generation BTK Inhibitor
- Updates in the Management of Chronic Lymphocytic Leukemia: a Focus on Targeted Therapies a Presentation for Healthtrust Members June 19, 2020
- Managing Drug Interactions with Oral Oncolytics in the Management of Hematologic Malignancies
- Meet AZN Management: Oncology 2021 ASCO Annual Meeting Dave Fredrickson, Executive Vice President, Oncology Business Unit
- June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
- The Specific Bruton Tyrosine Kinase Inhibitor Acal- Mechanisms of Anti-CD20 Antibodies
- Phase II Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
- Acute Myeloid Leukemia (AML)
- Calquence) Reference Number: CP.PHAR.366 Effective Date: 03.01.19 Last Review Date: 02.21 Line of Business: Commercial*, Medicaid Revision Log
- Tyrosine Kinase Inhibitors - Oral
- Policy Drug(S)
- Calquence (Acalabrutinib) – New Drug Approval
- Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease
- Hematologic Malignancies: Top Ten Advances Impacting Clinical Practice
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- Acalabrutinib Plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia
- Report Overpriced
- Acalabrutinib (ACP-196): a Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and in Vivo Potency Profile S
- Current Treatment Options in CLL
- Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use Between 2013 and 2017
- Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib
- Generic (Brand) Name Mechanism of Action Mechanism of Action
- Oncology Oral, Hematologic Cancers Therapeutic Class Review (TCR)
- Chemotherapeutic and Biologic Drugs
- Highlights in Chronic Lymphocytic Leukemia from the 62Nd American
- New Drug Updates in Hematologic Malignancies Rebecca J
- Differences and Similarities in the Effects of Ibrutinib and Acalabrutinib on Platelet Functions
- Kinase Inhibitors and Associated Cardiotoxicities
- Bruton Tyrosine Kinase Inhibitors for the Frontline Treatment of Chronic Lymphocytic Leukemia
- Targeting Bruton Tyrosine Kinase Using Non-Covalent Inhibitors in B Cell
- October MPU CENTRAL FINAL 2020.Docx
- BTK Gatekeeper Residue Variation Combined with Cysteine 481 Substitution Causes Super-Resistance to Irreversible Inhibitors Acalabrutinib, Ibrutinib and Zanubrutinib
- Highlights in Lymphoma from the 60Th American Society of Hematology Annual Meeting
- Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib As Potential Repurposed Drugs Against COVID-19
- Highlights in Chronic Lymphocytic Leukemia from the 2021 American